Skip to content

Innoviva, Inc. INVA Additional Paid-In Capital

Additional Paid-In Capital at other companies

Pfizer logo
PfizerPFE
$94.77B+1.0%
Insmed logo
InsmedINSM
$6.5B+37.9%
Savara logo
SavaraSVRA
$821.64M+23.7%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$772.21M+52.8%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$397.17M+16.6%
Alkermes logo
AlkermesALKS
$3.06B+4.9%

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total equity$1.3B
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K
Free cash flow$34.8M-28.4%

Valuation

See full
Market cap$1.74B+51.8%
Enterprise value$1.41B+9.7%
P/E3.5×
P/S4.2×+1.0×

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp
FCF margin54.1%+5.3pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio21.1×+18.7×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innoviva, Inc.'s additional paid-in capital?
Innoviva, Inc. (INVA) reported additional paid-in capital of $884.95M in Q1 2026.
How has Innoviva, Inc.'s additional paid-in capital changed year-over-year?
Innoviva, Inc.'s additional paid-in capital increased by 27.4% year-over-year, from $694.66M to $884.95M.
What is the long-term trend for Innoviva, Inc.'s additional paid-in capital?
Over 5 years (2020 to 2025), Innoviva, Inc.'s additional paid-in capital has grown at a -6.5% compound annual growth rate (CAGR), from $1.26B to $902.73M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.